Brendan Pang
Overview
Explore the profile of Brendan Pang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amanda S, Tan T, Ong J, Theardy M, Wong R, Huang X, et al.
Nat Commun
. 2022 May;
13(1):2420.
PMID: 35504924
IRF4 is a master regulator of immunity and is also frequently overexpressed in mature lymphoid neoplasms. Here, we demonstrate the oncogenicity of IRF4 in vivo, its potential effects on T-cell...
2.
Jain S, Sim W, Ng C, Chin Y, Lim W, Syn N, et al.
Front Oncol
. 2021 Oct;
11:736265.
PMID: 34631570
Purpose: Precision oncology, such as next generation sequencing (NGS) molecular analysis and bioinformatics are used to guide targeted therapies. The laboratory turnaround time (TAT) is a key performance indicator of...
3.
Toh J, Hoppe M, Thakur T, Yang H, Tan K, Pang B, et al.
BMJ Open Gastroenterol
. 2020 Aug;
7(1).
PMID: 32816956
Background: Differentiating between malignant and normal cells within tissue samples is vital for molecular profiling of cancer using advances in genomics and transcriptomics. Cell-surface markers of tumour-normal discrimination have additional...
4.
Heong V, Tay D, Goh S, Wee B, Tan T, Soo R, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32560395
We investigate the feasibility of obtaining multiple spatially-separated biopsies from a single lesion to explore intratumor heterogeneity and identify actionable truncal mutations using whole exome sequencing (WES). A single-pass radiologically-guided...
5.
Lui S, Iyengar P, Jaynes P, Bin Adam Isa Z, Pang B, Tan T, et al.
EMBO Rep
. 2020 Jan;
21(1):e49618.
PMID: 31910334
No abstract available.
6.
Lui S, Iyengar P, Jaynes P, Bin Adam Isa Z, Pang B, Tan T, et al.
EMBO Rep
. 2019 Dec;
21(1):e47269.
PMID: 31858684
No abstract available.
7.
Parris B, Shaw E, Pang B, Soong R, Fong K, Soo R
Respirology
. 2019 Jan;
24(3):215-226.
PMID: 30636374
The development of molecular testing for identifying somatic mutations and immune checkpoint biomarkers has directed treatment towards personalized medicine for patients with non-small cell lung cancer. The choice of molecular...
8.
Lin L, Huang M, Shi X, Mayakonda A, Hu K, Jiang Y, et al.
Nucleic Acids Res
. 2018 Nov;
47(3):1255-1267.
PMID: 30496486
As the second most common malignant bone tumor in children and adolescents, Ewing sarcoma is initiated and exacerbated by a chimeric oncoprotein, most commonly, EWS-FLI1. In this study, we apply...
9.
Chuah K, Pang B, Lim D, Lee C, Chau C
Pathology
. 2018 Oct;
50(7):779-782.
PMID: 30314647
No abstract available.
10.
Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes P, Iyengar P, et al.
J Exp Med
. 2018 Jun;
215(7):1913-1928.
PMID: 29880484
RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated...